Unique Environment

Precision Oncology

Molecular Mechanisms


Translation and Reverse Translation

Spirit of collaboration

Exceptional Career Opportunities

Interdisciplinary Education

Team Culture

Bottom-up Ideas

Shared Cutting Edge Resources

Research at FCI

Clinical Translation Programs
Strategic Core of FCI

Multidisciplinary teams consisting of clinicians, tumor biologists, biochemists, chemists and bioinformaticians work together in these interdisciplinary research projects. The teams rely on the technology platforms provided by the five research areas.

Read more

Molecular Diagnostic and Biomarker

The goal of Research Area 1 is to find individual parameters that can improve the diagnosis of tumors or better predict the response to therapy. For example, the composition of all proteins in a cell can be qualitatively and quantitatively analyzed by means of mass spectrometry.

Read more

Molecular Mechanisms of Tumor Pathogenesis

Elucidating the underlying causes of the individually different treatment responses in order to develop new therapeutic or diagnostic concepts based on the findings, is a fundamental goal of Research Area 2. To achieve this goal, it is essential to understand the molecular mechanisms that drive tumor development and progression. Research Area 2 combines the expertise in structural biology, biochemistry and cell biology within the FCI to analyze the tumorigenesis, the response to therapy and resistance mechanisms systematically and functionally in the overall cellular context at the molecular level. In line with the interdisciplinarity of the FCI, the molecular-pathophysiological mechanisms that underlie the clinical observations are elaborated on the basis of individual tumor samples.

Read more

Preclinical Models

This area is the essential link transferring new therapeutic strategies to the clinic. Far too often, promising substances fail in later clinical development. The lack of meaningful preclinical models is an important reason for this low success rate. The aim of Research Area 3 is therefore to develop new models enhancing the clinical success of a drug identified in basic research by better predicting the response in patients.

Read more

Drug Development and Novel Therapeutic Approaches

The goal of Research Area 4 is to develop new therapeutic approaches and to advance them to the development of new drugs. The extensive chemical, pharmaceutical and structural biology expertise at the Goethe University in Frankfurt enables the development and optimization of new drug candidates against validated target structures. At the Georg-Speyer-Haus and at the Paul Ehrlich Institute, innovative "biologicals" and cell therapeutics are being developed for which there are certified production areas at the Institute of Transfusion Medicine.

Read more

Clinical Trials

The integration of clinical trials into FCI is essential both as an end point of drug development and as a starting point for research on response and resistance mechanisms. The aim is to initiate such studies in close cooperation with the University Cancer Center (UCT). UCT Frankfurt has been continuously working on the development of a comprehensive clinical research unit, which will be fully available to the FCI. The practical implementation of early translational studies at the FCI site is guaranteed.

Read more

Discovery & Development

The primary objective of this program is to address excellent hypotheses on basic biological mechanisms of tumorigenesis, progression, diagnosis, and therapy.

Read more


Finding new targets for colorectal cancer using genetic mouse models

Owen Sansom, Beatson Institute for Cancer Research; University of Glasgow, Florian Greten

Speaker: Owen Sansom
Institution: Beatson Institute for Cancer Research; University of Glasgow
Organization: Florian Greten

Imaging tumour metabolism – From mouse to man

Kevin Brindle, Cancer Research UK Cambridge Institute, Canan Arkan

Speaker: Kevin Brindle
Institution: Cancer Research UK Cambridge Institute
Organization: Canan Arkan

Frankfurt Cancer Conference

24-08-2021 bis 26-08-2021
Various,, Thomas Oellerich, Christian Brandts and the Organising Committee
Goethe University Frankfurt Campus Westend / Auditorium Complex ("Hörsaalzentrum")

Speaker: Various
Organization: Thomas Oellerich, Christian Brandts and the Organising Committee

Press Releases


Hind Medyouf participates in the European Innovative Training Network INTERCEPT-MDS

Zum Artikel


New publication by Mohammed Mosa and Henner Farin about a phenotypic switch in the tumormicroenvironment in colorectal cancer

Zum Artikel


Fabian Finkelmeier receives DGVS research prize for his work on hepatocellular carcinoma

Zum Artikel